undefined undefined
NaN.000
NaN.00%
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.
05-18 01:47
FDA以最快的步伐加速批准了美国医药巨头百时美施贵宝(BMY.US)旗下的重磅创新型细胞疗法Breyanzi (lisocabtagene maraleucel)治疗滤泡性淋巴瘤患者。
05-16 14:58
为缩减成本,寻求新的市场增长点,精简产品管线也是跨国药企的一项重要手段。 近日,百时美施贵宝(BMS)在其第一季度报告中表示,计划在2025年底前通过大...
05-15 05:00
①在标普500指数成分股中,已有229家公布财报,其中近八成业绩好于市场预期,这使得市场对美股企业的盈利预估更为乐观; ②在已公布财报的“四巨头”中,Meta和特斯拉的财报及股东电话会表现仿佛镜像翻转,股价也走上截然相反的道路。
04-28 17:41
美國藥廠百時美施貴寶(BMY.US)公布首季業績。季度虧損119.11億美元,對上年度同期純利22.62億美元。每股季度虧損5.89美元。季度收入按年升4.7...
04-26 09:46
Shares of Bristol-Myers Squibb dipped in the premarket Thursday even as the company’s Q1 2024 results exceeded expectations amid headwinds to key components in its growth portfolio dominated by its ca...
04-25 19:56
Cerevel Therapeutics周四宣布,其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。
04-18 21:25
AbbVie’s (NYSE:ABBV) buyout target, Cerevel Therapeutics (NASDAQ:CERE), announced Thursday that its oral, once-daily Parkinson’s disease candidate, tavapadon, reached its main goals in a pivotal Phase...
04-18 19:00
Bristol Myers Squibb (NYSE:BMY) announced Saturday that its experimental schizophrenia therapy KarXT, acquired as part of its recent Karuna Therapeutics buyout, indicated a well-tolerated safety profi...
04-07 03:21